Print Page  Close Window

Investor Relations
Corporate Profile

We are Zogenix.

Zogenix is committed to developing therapies that address specific clinical needs for people living with CNS and pain-related conditions who need innovative treatment alternatives to help them return to normal daily functioning.

A significant number of patients are not being effectively treated, despite the availability of current therapies. These patients deserve access to safe and effective treatments. Zogenix is committed to ensuring the safe and appropriate use of our products ... More >>

Latest PresentationsMore >>
Title
Download Documentation Zogenix December 2014 Investor Presentation
Get help downloading or viewing the above file types
Stock Quote
ZGNX (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$1.25
Change (%) Stock is Up 0.05 (4.17%)
Volume1,661,279
Data as of 12/26/14 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent NewsMore >>
DateTitle 
12/03/14Zogenix to Participate in Oppenheimer 25th Annual Healthcare Conference
SAN DIEGO, Dec. 3, 2014 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related conditions and central nervous system disorders, today announced that Stephen Farr, President, and Ann Rhoads, Chief Financial Officer, will present at the Oppenheimer 25th Annual Healthcare Conference in New York, NY on December 10, 2014. Event: Oppenheimer 25th Annual Healthcare Conference Date:   Wednesday, Dec... 
Printer Friendly Version
12/01/14Results of Long-Term, Open-Label Study Published in the Journal of Pain Research Demonstrate the Safety, Tolerability and Effectiveness of Zohydro(R) ER
Findings Contribute to Growing Body of Evidence Supporting Efficacy and Safety Profile SAN DIEGO, Dec. 1, 2014 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related and central nervous system (CNS) disorders, today announced the publication of a long-term Phase 3 open-label study, which showed that Zohydro® ER (hydrocodone bitartrate) Extended-Release Capsules, CII, were generally safe, well-tolerated ... 
Printer Friendly Version
11/12/14Zogenix to Participate in Stifel 2014 Healthcare Conference
SAN DIEGO, Nov. 12, 2014 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related conditions and central nervous system disorders, today announced that Zogenix management will present at the Stifel 2014 Healthcare Conference in New York, NY on November 18, 2014. Event: Stifel 2014 Healthcare Conference Date: Tuesday, November 18, 2014 ... 
Printer Friendly Version
11/06/14Zogenix Reports Third Quarter 2014 Financial Results
Conference Call and Webcast Today, November 6, at 4:30 p.m. ET Recent Business Highlights Submitted a supplemental New Drug Application (sNDA) for a modified formulation with potential abuse deterrent properties of Zohydro® ER (hydrocodone bitartrate) Extended-Release Capsules, CII, on September 30, with a target action date in late January 2015   Acquired Brabant Pharma, obtaining global rights for a Phase 3 product candidate with orphan drug designation in the U.S. and ... 
Printer Friendly Version
Upcoming EventsMore >>
There are currently no events scheduled.

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.